Cost-effectiveness of treatments for diabetic macular oedema: Should we pay more attention to the appraisal and reporting of economic evaluations?

British Journal of Ophthalmology

Volumn 98, Issue 4, 2014, Pages 421-422

  Virgili, Gianni ^a   Parravano, Mariacristina ^b   Menchini, Francesca ^c   Brunetti, Massimo ^d  

^a UNIVERSITY OF FLORENCE   (Italy)

^b IRCCS FONDAZIONE BIETTI   (Italy)

^c UNIVERSITY HOSPITAL OF UDINE   (Italy)

^d Organization Development Local Health Unit Modena   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR;

ANTIANGIOGENIC THERAPY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ECONOMIC EVALUATION; EDITORIAL; LASER COAGULATION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; VISUAL ACUITY; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH STATUS; HUMAN; MACULAR EDEMA; OUTCOME ASSESSMENT; SOCIOECONOMICS;

ANGIOGENESIS INHIBITORS; COST-BENEFIT ANALYSIS; DIABETIC RETINOPATHY; HEALTH STATUS; HUMANS; MACULAR EDEMA; OUTCOME ASSESSMENT (HEALTH CARE); VALUE OF LIFE;

EID: 84896548175     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2013-303352     Document Type: Editorial

References (9)

1. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984;91:1464-74.
2. Virgili G, Parravano M, Menchini F, et al. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database Syst Rev 2012(12):CD007419.
3. National Institute for Health and Clinical Excellence. Ranibizumab for the treatment of diabetic macular oedema Issued: November 2011 NICE technology appraisal guidance 237. http://www.nice.org.uk/ nicemedia/live/13125/55324/ 55324.pdf (accessed 20 Sep 2012).
4. Mitchell P, Annemans L, Gallagher M, et al. Cost- effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. Br J Ophthalmol 2012;96:688-93.
5. Philips Z, Ginnelly L, Sculpher M, et al. Review of guidelines for good practice in decision-Analytic modelling in health technology assessment. Health Technol Assess 2004;8:1-158.
6. Garattini L, Koleva D, Casadei G. Modeling in pharmacoeconomic studies: funding sources and outcomes. Int J Technol Assess Health Care 2010;26:330-3.
7. National Institute for Health and Clinical Excellence. Ranibizumab for the treatment of diabetic macular oedema (rapid review of TA237). http://guidance.nice. org.uk/TA/Wave23/41 (accessed 21 Oct 2012).
8. Anderson R. Systematic reviews of economic evaluations: utility or futility? Health Econ 2010;19:350-64.
9. Brunetti M, Shemilt I, Pregno S, et al. GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence. J Clin Epidemiol 2013;66:140-50.